$MDXG (MiMedx Group, Inc.)

$MDXG {{ '2016-06-27T14:49:00+0000' | timeago}} • Announcement

$MDXG said it has agreed to terms of settlement with each of Medline Industries and Liventa Bioscience for false advertising claims asserted against each of them by $MDXG. In April 2014, $MDXG filed a lawsuit in Northern District Court of Georgia against Musculoskeletal Transplant Foundation, Medline, and Liventa for permanent injunctive relief.

$MDXG {{ '2018-01-16T15:33:54+0000' | timeago}} • Announcement

$MDXG announced the first patients have been randomized and enrolled in the pivotal Phase 3 Investigational New Drug clinical trial to assess the safety and efficacy of AmnioFix Injectable in patients with recalcitrant plantar fasciitis pain, which is most common in chronic heel pain in adults. Top-line results from this study are expected in 2H19.

$MDXG {{ '2018-01-11T20:52:15+0000' | timeago}} • Announcement

$MDXG successfully settled its longstanding patent infringement lawsuit against Musculoskeletal Transplant Foundation, Inc., Medline Industries, Inc. and Liventa Bioscience, Inc. The company has obtained a Consent Decree and Final Judgment on the validity of the patent and will receive an undisclosed monetary sum.

$MDXG {{ '2018-01-08T13:35:17+0000' | timeago}} • Announcement

$MDXG, a biopharmaceutical company, said it estimates 4Q17 revenues to be $90.9MM, up 30% compared to last year. For fiscal 2017, the company sees revenue of $324.5MM, higher by 32% from last year.

$MDXG {{ '2017-12-19T13:55:26+0000' | timeago}} • Announcement

$MDXG agreed to a confidential lawsuit settlement from one former employee, William Mills, who voluntarily resigned from MiMedx in January 2017. $MDXG alleged that Mills breached his restrictive covenants and his duty of loyalty by selling another company's medical products while employed by MiMedx.

$MDXG {{ '2017-12-13T13:32:51+0000' | timeago}} • Announcement

Pharma company $MDXG said FY18 revenue is likely to be between $383MM and $387MM. GAAP earnings per share is estimated to be in the range of $0.30 to $0.35, and non GAAP earnings between $0.45 per share and $0.50 per share. MiMedx is looking for gross profit margin in the range of 89% to 90% for the year, and operating income in the 15-17% range.

$MDXG {{ '2017-11-17T16:16:27+0000' | timeago}} • Announcement

$MDXG reiterated its 4Q17 revenue outlook of $87-88MM. The company reiterated its 2017 revenue estimate of $320.6-321.6MM, gross margin forecast of 89-90%, and GAAP EPS guidance of $0.31-0.32.

$MDXG {{ '2017-10-17T15:58:07+0000' | timeago}} • Announcement

$MDXG warned that certain individuals or entities not associated with the company are establishing fake email accounts to impersonate company executives. The company warns that emails purporting to be from $MDXG executives from non-MiMedx email accounts should be viewed sceptically and brought to its notice. The issue is being investigated.

$MDXG {{ '2017-10-17T12:38:30+0000' | timeago}} • Announcement

$MDXG, a pharmaceutical firm, said it received green signal from the FDA to proceed with the Investigational New Drug study of AmnioFix, an injectable formulation for  the treatment of knee osteoarthritis, in comparison with saline placebo. The company expects patient enrollment in the the phase-2B study to commence next quarter.

$MDXG {{ '2017-10-10T14:24:36+0000' | timeago}} • Announcement

$MDXG announced its preliminary revenue results for 3Q17. The company recorded revenue of $84.6MM, up 31% over 3Q16. Revenue from the direct sales force is in excess of 95% of total revenue with revenue from distributors and Original Equipment Manufacturer (OEM) accounts below 5% of total revenue. YTD revenue grew 33% to $233.6MM vs. last year.

$MDXG {{ '2017-10-09T12:45:46+0000' | timeago}} • Announcement

$MDXG's BoD has authorized a $10MM increase in the company's share repurchase program, bringing the total authorized to $110MM since the commencement in May 2014.

$MDXG {{ '2017-10-04T15:20:48+0000' | timeago}} • Announcement

$MDXG and one of its employees have filed a lawsuit against Viceroy Research and Sparrow Fund Research LP a/k/a Aurelius Value, John Fichthorn, BR Dialectic Capital Management, LLC, and "Does" 1-10, for libel, slander, defamation, false light, and tortious interference with business relations.

$MDXG {{ '2017-10-03T15:04:14+0000' | timeago}} • Announcement

$MDXG appointed Gloria Matthews as its SVP, Research and Development. Matthews will lead the company's overall research function as well as the development of new products. The company also reaffirmed its previously communicated revenue expectations for 3Q17.

$MDXG {{ '2017-10-02T18:55:33+0000' | timeago}} • Announcement

$MDXG divested its subsidiary, Stability Biologics LLC back to the former stockholders of Stability Inc. The transaction closed on Sept. 30, 2017. The consideration included a promissory note issued by Stability Biologics for $3.5MM and a waiver of all claims and rights to any earn-out consideration. $MDXG expects to book a one-time gain.

$MDXG {{ '2017-10-02T14:00:41+0000' | timeago}} • Announcement

$MDXG said Northern District Court of Georgia has set a trial date of Jan. 22, 2018 for the company's patent infringement lawsuit against Musculoskeletal Transplant Foundation, Medline Industries, and Liventa Bioscience.

$MDXG {{ '2017-09-19T15:22:20+0000' | timeago}} • Announcement

$MDXG has filed with the FDA to initiate its Investigational New Drug (IND) Phase 2 clinical trial for osteoarthritis of the knee. The objective is to determine the safety and effectiveness of AmnioFix Injectable as compared to the 0.9% Sodium Chloride USP placebo injection control for the treatment of knee osteoarthritic pain.

$MDXG {{ '2017-09-13T13:59:54+0000' | timeago}} • Announcement

$MDXG said its production operations in Georgia and placenta recovery functions are operating normally, and its previously published expectation for 3Q17 revenue to exceed the $80MM mark is unaffected by Hurricane Irma. $MDXG remains confident in its ability to meet or exceed revenue projections for 2017, which are at $309-311MM range.

$MDXG {{ '2017-09-07T14:14:35+0000' | timeago}} • Announcement

$MDXG said it received green signal from the FDA to proceed with a new drug phase-3 clinical study of its AmnioFix injection, for the treatment of Achilles Tendonitis. MiMedx expects to commence patient enrollment in the next quarter. The objective of the study is to determine the safety and effectiveness of the formulation, compared to placebo.

$MDXG {{ '2017-09-05T17:12:01+0000' | timeago}} • Announcement

Biopharmaceutical company $MDXG said that its expectation for 3Q17 revenue is expected to exceed $80MM, the high end of its 3Q17 revenue guidance range. The company previously guided to a 3Q17 revenue range of $79-80MM. The updated guidance is based on the strength of its July and August revenue performance.

$MDXG {{ '2017-08-31T13:03:59+0000' | timeago}} • Announcement

Pharma firm $MDXG said its latest peer-reviewed study of MiMedx dehydrated human amnion/chorion membrane (EpiFix) allografts was accepted for publication in the International Wound Journal. Patients treated with EpiFix showed VLU healing rates of 60% within 12 weeks and 71% within 16 weeks - a superior healing rate compared to the other studies.

$MDXG {{ '2017-08-18T19:33:28+0000' | timeago}} • Announcement

$MDXG will divest its Stability Biologics subsidiary as part of its strategic focus on biopharma. The company expects to book a one-time gain on this transaction of approx. $8-10MM. If the deal closes in 3Q17, $MDXG will maintain its FY17 revenue guidance of $309-311MM. $MDXG is reaffirming all guidance ranges for 3Q17 and FY17.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
ZBH (Zimmer Biomet Holdings, Inc.)
Wednesday, November 1 2017 - 12:00pm
MDXG (MiMedx Group, Inc.)
Friday, October 27 2017 - 2:30pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
MMM (3M Company)
Tuesday, October 24 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm

AlphaGraphics you may like